Seems to me that when a Legislative Bill presents with an incipient flood of CMS monies for non-opioid treatments, and the greater the push by influentials to start it all in 2024 rather than the scheduled 2025, the greater the shoutdowns become that a 5-FDA approved/turn-key company won’t ever be considered.
…opinions are a dime a dozen….
Here’s one:
>>>Any potential buyer/merger candidate would read BIEL's financial statements and laugh out loud.…That's all the evidence an experienced biotech or biopharma needs to see.<<<
Here’s another:
A prospective buyer or partner, already well-established and moneyed in the Pain space, should always and astutely be on the lookout for opportunities, and look well-beyond the financial statements of the possible target acquisition (in this example BIEL). Appraising the POTENTIAL value of that target for the ACQUIRER in light of a political/legislative/CMS-Insurance-Government reimbursement money spigot coming into view on the radar is the task at hand. Not sales.
ADDITIONALLY, that prospective buyer should survey their well-established and moneyed COMPETITORS, especially should one of those competitors pre-empt them via the acquisition or merger.
Why should they care? Because nobody likes a pre-empt that results in another appreciably eating into their profits. Oh no!
So, I like the latter opinion.
As ever, and said prior, no guarantees.
Yet, nothing ventured, nothing gained.
All imo.
News 
Market Data 
Discover 
AI
